Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI310 plus Sintilimab in Advanced NSCLC
NCT05118334Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Nov 2021
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of IBI310 in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Innovent Biologics. Primary endpoints: Objective Response Rate up to 2 years, Treatment Emergent Adverse Event up to 2 years and 1 more. Started Nov 2021; status: completed.
02
Drugs
IBI310
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05118334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05118334.